Moderna, Inc. (MRNA)
Overview · Option chain · Volatility · Expected-move history · Earnings
Cboe delayed options data · as of 06:40 UTC · Figures derived from the full chain (1,844 contracts, 16 expirations) · IV own-history percentile appears after 60 recorded days (28 so far)
Expected move · Nov 20, 2026 (32 days)
Methodology →Read from option prices: the at-the-money straddle costs this much, so the market is pricing a move of about that size in either direction by this date. It is an estimate of movement, not a prediction of direction.
Options are pricing a move of about ±27.2% (range 157.03–274.57) by Nov 20, 2026. ATM straddle: 58.77 @ strike 220 · ATM IV: 109.1%.
Probability distribution
Model & assumptions →The curve shows where a lognormal model, fed with current implied volatility, puts the range of outcomes at this expiration. Shaded: the expected-move band.
| Level | vs price | P(above)Model-estimated chance the stock finishes above a level at expiration, derived from current IV under a lognormal model with stated assumptions — an estimate, not a prediction. | P(below) |
|---|---|---|---|
| 194.22 | -10% | 56.5% | 43.5% |
| 205.01 | -5% | 49.9% | 50.1% |
| 215.80 | +0% | 43.6% | 56.4% |
| 226.59 | +5% | 37.7% | 62.3% |
| 237.38 | +10% | 32.4% | 67.6% |
Model-estimated probabilities of finishing above/below each level at expiration: estimates under stated assumptions, not predictions.
Probability explorer
Drag the slider to any level and see the model-estimated chance the stock finishes above or below it at the selected expiration.
Horizon: Nov 20, 2026 · lognormal model with zero drift: an estimate, not a prediction. Assumptions
Expirations
Open the chain →| Expires | DTEDays to expiration, in calendar days. | Implied move | ATM IV | Open int. |
|---|---|---|---|---|
| Oct 23, 2026 | 4 | ±10.5% | 93.5% | 51.4K |
| Oct 30, 2026 | 11 | ±21.7% | 138.6% | 35.0K |
| Nov 06, 2026 | 18 | ±24.0% | 125.5% | 5,411 |
| Nov 13, 2026 | 25 | ±25.3% | 115.1% | 3,124 |
| Nov 20, 2026 | 32 | ±27.2% | 109.1% | 117.1K |
| Nov 27, 2026 | 39 | ±27.8% | 103.1% | 890 |
| Dec 18, 2026 | 60 | ±31.3% | 93.8% | 130.5K |
| Jan 15, 2027 | 88 | ±35.9% | 89.9% | 210.5K |
| Feb 19, 2027 | 123 | ±40.9% | 87.3% | 2,132 |
| Mar 19, 2027 | 151 | ±44.9% | 87.1% | 57.5K |
| Apr 16, 2027 | 179 | ±48.1% | 86.1% | 12.5K |
Open interest by strike · Nov 20
Where option positions are concentrated. Teal bars are calls, red bars are puts; the dashed line is the current price.
Largest open-interest concentrations (all expirations ≤ 60 days): 150 P · 12.3K200 C · 10.9K250 C · 8,079220 C · 8,025160 P · 8,018
IV term structure
Volatility page →At-the-money implied volatility for each expiration. A hump around a date often marks a scheduled event the market is pricing.
When does open interest expire?
Implied vs realized volatility
HV from our stored daily closes (annualized); IV30 interpolated from the chain. Method
Price, last 60 sessions
Daily closes; Financial Modeling Prep.
Track record
Full history →Of 93 recorded snapshot-versus-outcome comparisons so far, the close landed inside the expected range 31.2% of the time.
Past earnings reactions
Avg |reaction| 9.8% · median 8.1% (20 reports). Two-session close-to-close window; definition
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strate
Healthcare · Biotechnology · NASDAQ · Profile: Financial Modeling Prep
Related securities · Healthcare
UNH · IV 31.7%HIMS · IV 89.0%PFE · IV 26.0%LLY · IV 40.7%JNJ · IV 23.4%MRK · IV 36.9%